

Four-Coordinate Triarylborane Synthesis via Cascade B-Cl/C-B Cross-Metathesis and C-H Bond Borylation





Kai Yang,^a Guan Zhang,^a Qiuling Song^{*a,b}

^a Institute of Next Generation Matter Transformation, College of Chemical Engineering, College of Material Sciences Engineering at Huaqiao University, 668 Jimei Boulevard, Xiamen, Fujian 361021, P. R. China


^b State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P. R. China.

General. All experiments were conducted with a schlenk tube. Flash column chromatography was performed over silica gel (200-300 mesh). ¹H NMR and ¹³C NMR spectra were recorded at ambient temperature using Bruker AVIII-500M spectrometers, chemical shifts (in ppm) were referenced to CDCl₃ (δ = 7.26 ppm), DMSO-d₆ (δ = 2.50 ppm) and acetone-d₆ (δ = 2.05 ppm) as internal standards. ¹³C NMR spectra were obtained by using the same NMR spectrometers and were calibrated with CDCl₃ (δ = 77.0 ppm), DMSO-d₆ (δ = 39.5 ppm) and acetone-d₆ (δ = 206.68 ppm). The amines was prepared from the corresponding 2-bromopyridine with arylamines according to previous literature.¹ The potassium aryltrifluoroborates were prepared from the corresponding arylboronic acids and KF₂H. Unless otherwise noted, materials obtained from commercial suppliers were used without further purification.

¹ Y., Onoda, M., Suzuki and T., Kanbara, JP 2009286716



Supplementary Figure 1. Control experiment for probable intermediate. **a** 2 (0.48 mmol), SiCl_4 (0.2 mmol), $i\text{Pr}_2\text{NEt}$ (0.72 mmol), 135 °C, toluene (1 mL), 4.5 h; **b** 2 (0.48 mmol), SiCl_4 (0.2 mmol), 135 °C, toluene (1 mL), 4.5 h.



Supplementary Scheme 1. Symmetric molecule (BAr^12 or BAr^22) was not detected in our reaction when only added one electron-rich potassium aryltrifluoroborate or electron-deficient potassium aryltrifluoroborate.

Supplementary Table 1. quantum yields of some four-coordinate triarylborane products in DCM and solid state

number	quantum yields in DCM (%)	quantum yields in solid state (%)
3	28.87	42.07
7	17.63	22.75
17	0.52	28.94
29	23.96	39.14
32	33.28	48.24
47	17.65	20.33
49	1.49	19.66

General procedure A for the preparation of four-coordinate triarylborane products from amines and potassium aryltrifluoroborates.

In air, a 25 mL schlenk tube was charged with amine (0.2 mmol, 1 equiv) and potassium aryltrifluoroborates (0.48 mmol, 2.4 equiv). The tube was evacuated and filled with nitrogen for three cycles. Then, toluene (1 mL), SiCl_4 (0.2 mmol, 24 μl , 1 equiv) and $i\text{Pr}_2\text{NEt}$ (0.72 mmol, 119 μl , 3.6 equiv) was added at room temperature. The reaction was allowed to stir at corresponding temperature for 3 hours. Upon completion, the reaction was cooled to room temperature and proper amount of silica gel was added. After removal of the solvent, the crude reaction mixture was purified


on silica gel (petroleum ether: ethyl acetate = 5:1-1:1) to afford the desired product.

General procedure B for the preparation of four-coordinate triarylborane products from 2-aryl-pyridines and potassium aryltrifluoroborates.

In air, a 25 mL schlenk tube was charged with 2-aryl-pyridine (0.2 mmol, 1 equiv) and potassium aryltrifluoroborates (0.72 mmol, 3.6 equiv). The tube was evacuated and filled with nitrogen for three cycles. Then, toluene (1 mL), SiCl₄ (0.2 mmol, 24 µl, 1 equiv) and iPr₂NEt (1 mmol, 165 µl, 5 equiv) was added at room temperature. The reaction was allowed to stir at corresponding temperature for 3 hours. Upon completion, the reaction was cooled to room temperature and proper amount of silica gel was added. After removal of the solvent, the crude reaction mixture was purified on silica gel (petroleum ether: ethyl acetate = 5:1-1:1) to afford the desired product.

General procedure C for the preparation of four-coordinate triarylborane products from amines and two different potassium aryltrifluoroborates.

In air, a 25 mL schlenk tube was charged with amine (0.2 mmol, 1 equiv), potassium aryltrifluoroborates **2** (0.24 mmol, 1.2 equiv) and potassium aryltrifluoroborates **4** (0.24 mmol, 1.2 equiv). The tube was evacuated and filled with nitrogen for three cycles. Then, toluene (1 mL), SiCl₄ (0.2 mmol, 24 µl, 1 equiv) and iPr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) was added at room temperature. The reaction was allowed to stir at corresponding temperature for 3 hours. Upon completion, the reaction was cooled to room temperature and proper amount of silica gel was added. After removal of the solvent, the crude reaction mixture was purified on silica gel (petroleum ether: ethyl acetate = 5:1-1:1) to afford the desired product.




6,6-diphenyl-6,11-dihydro-5H,6H-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 3.

The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), iPr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 51 mg of the product as a white solid (75%). mp 240-241 °C. ¹H NMR (500 MHz, acetone) δ 9.56 (s, 1H), 7.83-7.81 (m, 1H), 7.74 (d, *J* = 6.3 Hz, 1H), 7.19 – 6.98 (m, 13H), 6.94 – 6.86 (m, 2H), 6.83 (d, *J* = 7.9 Hz, 1H). ¹³C NMR (126 MHz, acetone) δ 152.7, 144.7, 141.4, 139.6, 135.2, 128.2, 127.0, 126.2, 124.4, 115.5,


114.8, 114.4. ^{11}B NMR (160 MHz, Acetone) δ -1.21. HRMS (ESI) m/z calcd for C₂₃H₂₀BN₂ [M+H]⁺: 335.1714, found 335.1716.



6-fluoro-6-phenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 4. white solid. mp 249-251 °C. ^1H NMR (500 MHz, Acetone) δ 9.89 (s, 1H), 7.99 (d, J = 6.1 Hz, 1H), 7.88 – 7.72 (m, 1H), 7.33-7.28 (m, 3H), 7.20 (d, J = 8.7 Hz, 1H), 7.18 – 7.10 (m, 3H), 7.09-7.04 (m, 1H), 7.00-6.95 (m, 2H), 6.90 (t, J = 6.6 Hz, 1H). ^{13}C NMR (126 MHz, acetone) δ 150.7, 142.4, 141.6, 138.8, 138.7, 134.4, 132.5, 132.5, 128.3, 118.2, 126.9, 124.3, 115.5, 115.1, 114.9. ^{19}F NMR (471 MHz, Acetone) δ -168.7. ^{11}B NMR (160 MHz, acetone) δ 4.23. HRMS (ESI) m/z calcd for C₁₇H₁₄BFN₂Na [M+Na]⁺: 299.1126, found 299.1127.




8-methyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 5. The general procedure A was followed by using *N*-(*p*-tolyl)pyridin-2-amine (36.8 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μ l, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 μ l, 3.6 equiv) and toluene (1 mL) to afford 37 mg of the product as a white solid (53%). mp 237-238 °C. ^1H NMR (500 MHz, CDCl₃) δ 7.78 (dd, J = 6.3, 1.5 Hz, 1H), 7.52-7.49 (m, 1H), 7.26 – 7.20 (m, 4H), 7.20 – 7.10 (m, 6H), 6.95 (s, 1H), 6.88 (dd, J = 7.9, 1.5 Hz, 1H), 6.79 (s, 1H), 6.69 – 6.66 (m, 1H), 6.49 (t, J = 7.9 Hz, 2H), 2.24 (s, 3H). ^{13}C NMR (126 MHz, CDCl₃) δ 150.5, 143.7, 139.3, 135.0, 134.6, 134.0, 132.9, 127.1, 126.5, 125.3, 114.0, 112.8, 112.6, 21.1. ^{11}B NMR (160 MHz, CDCl₃) δ -0.88. HRMS (ESI) m/z calcd for C₂₄H₂₂BN₂ [M+H]⁺: 349.1871, found 349.1870.




8-(tert-butyl)-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 6. The General procedure A was followed by using *N*-(*o*-tolyl)pyridin-2-amine (36.8 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μ l, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 μ l, 3.6 equiv) and toluene (1 mL) to afford 34 mg of the product as a white solid (49%). mp 179-180 °C. ^1H NMR (500 MHz, CDCl₃) δ 7.80 (dd, J = 6.3, 1.3 Hz, 1H), 7.49-7.45 (m, 1H), 7.26 – 7.21 (m, 5H), 7.19 – 7.14 (m, 6H), 7.10 (dd, J = 8.2, 2.3 Hz, 1H), 6.73 (s, 1H), 6.69 – 6.64 (m, 1H), 6.47 (d, J = 8.2 Hz, 1H), 6.42 (d, J = 8.6 Hz, 1H), 1.25 (s, 9H). ^{13}C NMR (126 MHz, CDCl₃) δ 150.6, 146.2, 143.6, 139.2, 135.1, 134.0, 131.3,


127.1, 125.2, 122.5, 114.0, 112.8, 112.2, 34.3, 31.5. ^{11}B NMR (160 MHz, CDCl_3) δ -0.77 (s). HRMS (ESI) m/z calcd for $\text{C}_{27}\text{H}_{28}\text{BN}_2$ [M+H] $^+$: 391.2340, found 391.2347.



8-isopropyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 7. The General procedure A was followed by using *N*-(4-isopropylphenyl)pyridin-2-amine (42 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 52 mg of the product as a white solid (69%). mp 188-189 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.77 (d, J = 5.4 Hz, 1H), 7.49-7.45 (m, 1H), 7.25 (dd, J = 11.5, 4.5 Hz, 4H), 7.21 – 7.12 (m, 6H), 7.02 (d, J = 1.8 Hz, 1H), 6.95 (dd, J = 8.0, 2.0 Hz, 1H), 6.78 (s, 1H), 6.70 – 6.63 (m, 1H), 6.48 (d, J = 8.0 Hz, 1H), 6.43 (d, J = 8.5 Hz, 1H), 2.83 (hept, J = 6.8 Hz, 1H), 1.19 (d, J = 6.9 Hz, 6H). ^{13}C NMR (126 MHz, CDCl_3) δ 150.6, 144.1, 143.6, 139.2, 135.4, 134.0, 132.6, 127.1, 125.3, 123.3, 114.0, 112.8, 112.7, 33.6, 24.2. ^{11}B NMR (160 MHz, CDCl_3) δ -0.66 (s). HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{26}\text{BN}_2$ [M+H] $^+$: 377.2184, found 377.2186.




9,10-dimethyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 8. The General procedure A was followed by using *N*-(2,3-dimethylphenyl)pyridin-2-amine (40 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 51 mg of the product as a white solid (71%). mp 226-227 °C. ^1H NMR (500 MHz, acetone) δ 8.68 (s, 1H), 7.83-7.79 (m, 1H), 7.71 (dd, J = 6.3, 1.4 Hz, 1H), 7.43 (d, J = 8.7 Hz, 1H), 7.19 – 7.00 (m, 10H), 6.98 – 6.86 (m, 1H), 6.75 (q, J = 7.5 Hz, 2H), 2.23 (s, 3H), 2.22 (s, 3H). ^{13}C NMR (126 MHz, Acetone) δ 153.0, 144.4, 141.1, 137.8, 135.2, 134.6, 132.5, 128.1, 126.3, 126.1, 120.1, 115.7, 115.6, 21.0, 13.3. ^{11}B NMR (160 MHz, acetone) δ -1.30 (s). HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{24}^{10}\text{BN}_2$ [M+H] $^+$: 362.2063, found 362.2062.




8,9-dimethyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 9. The General procedure A was followed by using *N*-(3,4-dimethylphenyl)pyridin-2-amine (40 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv)

and toluene (1 mL) to afford 38 mg of the product as a white solid (52%). mp 247-249 °C. ¹H NMR (500 MHz, acetone) δ 9.39 (s, 1H), 7.77 – 7.67 (m, 2H), 7.18 – 7.09 (m, 9H), 7.07-7.03 (m, 2H), 6.84 – 6.75 (m, 2H), 6.62 (s, 1H), 2.14 (s, 3H), 2.08 (s, 3H). ¹³C NMR (126 MHz, acetone) δ 152.6, 144.6, 141.0, 137.5, 136.3, 135.2, 134.7, 131.8, 128.1, 126.1, 115.6, 115.0, 114.7, 20.1, 20.0. ¹¹B NMR (160 MHz, acetone) δ -1.30 (s). HRMS (ESI) m/z calcd for C₂₅H₂₄¹⁰BN₂ [M+H]⁺: 362.2063, found 362.2061.




7,7-diphenyl-1,2,3,4,7,13-hexahydro-7l4,8l4-naphtho[2,1-c]pyrido[2,1-f][1,5,2]diazaborinine, **10**.

The General procedure A was followed by using *N*-(5,6,7,8-tetrahydronaphthalen-1-yl)pyridin-2-amine (44 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl, 3.6 equiv) and toluene (1 mL) to afford 57 mg of the product as a white solid (73%). mp 229-230 °C. ¹H NMR (500 MHz, acetone) δ 8.55 (s, 1H), 7.82-7.79 (m, 1H), 7.71 (dd, *J* = 6.3, 1.6 Hz, 1H), 7.49 – 7.42 (m, 1H), 7.14 – 7.07 (m, 8H), 7.07 – 7.02 (m, 2H), 6.89 (td, *J* = 7.0, 1.2 Hz, 1H), 6.76 (d, *J* = 7.5 Hz, 1H), 6.66 (d, *J* = 7.5 Hz, 1H), 2.68 (t, *J* = 6.5 Hz, 4H), 1.86-1.81 (m, 2H), 1.74-1.69 (m, 2H). ¹³C NMR (126 MHz, acetone) δ 152.9, 144.4, 141.1, 137.2, 135.4, 135.2, 132.4, 128.1, 126.1, 125.4, 120.9, 115.7, 115.6, 30.9, 25.1, 24.5, 24.0. ¹¹B NMR (160 MHz, acetone) δ -1.32. HRMS (ESI) m/z calcd for C₂₇H₂₆¹⁰BN₂ [M+H]⁺: 388.2220, found 388.2227.




8-fluoro-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, **11**.


The General procedure A was followed by using *N*-(4-fluorophenyl)pyridin-2-amine (37 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl, 3.6 equiv) and toluene (1 mL) to afford 20 mg of the product as a white solid (26%). mp 230-231 °C. ¹H NMR (500 MHz, acetone) δ 9.62 (s, 1H), 7.84-7.81 (m, 1H), 7.73 (d, *J* = 6.4 Hz, 1H), 7.19 – 7.12 (m, 5H), 7.13 – 7.06 (m, 6H), 6.91 – 6.85 (m, 2H), 6.80-6.76 (m, 1H), 6.67 (dd, *J* = 9.4, 2.9 Hz, 1H). ¹³C NMR (126 MHz, acetone) δ 161.1 (d, *J* = 237.5 Hz), 152.6, 144.5, 141.6, 135.9, 135.1, 128.4, 126.5, 120.5 (d, *J* = 19.9 Hz), 115.8 (d, *J* = 7.5 Hz), 115.7, 114.8, 113.5 (d, *J* = 23.8 Hz). ¹¹B NMR (160 MHz, acetone) δ -1.34 (s). HRMS (ESI) m/z calcd for C₂₃H₁₈BFN₂Na [M+Na]⁺: 375.1439, found 375.1441.



8-chloro-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 12. The General procedure A was followed by using *N*-(4-chlorophenyl)pyridin-2-amine (40 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), $i\text{Pr}_2\text{NEt}$ (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 35 mg of the product as a white solid (47%). mp 249-250 °C. ^1H NMR (500 MHz, DMSO) δ 10.59 (s, 1H), 7.85-7.81 (m, 1H), 7.59 (d, J = 6.2 Hz, 1H), 7.18 – 7.10 (m, 5H), 7.10 – 7.04 (m, 3H), 7.02 – 6.95 (m, 4H), 6.91 – 6.83 (m, 2H), 6.74 (d, J = 2.4 Hz, 1H). ^{13}C NMR (126 MHz, DMSO) δ 150.4, 142.7, 140.6, 136.8, 133.3, 132.2, 127.1, 126.7, 125.5, 125.2, 115.0, 114.7, 113.5. ^{11}B NMR (160 MHz, DMSO) δ -2.23. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{BClN}_2$ [M+H]⁺: 369.1324, found 369.1322.




8-bromo-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 13. The General procedure A was followed by using *N*-(4-bromophenyl)pyridin-2-amine (49.6 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), $i\text{Pr}_2\text{NEt}$ (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 28 mg of the product as a white solid (34%). mp 257-258 °C. ^1H NMR (500 MHz, acetone) δ 9.69 (s, 1H), 7.87-7.84 (m, 1H), 7.75 (dd, J = 6.4, 1.5 Hz, 1H), 7.21 – 7.13 (m, 6H), 7.13 – 7.03 (m, 7H), 6.97 – 6.89 (m, 1H), 6.82 (d, J = 8.4 Hz, 1H). ^{13}C NMR (126 MHz, acetone) δ 152.5, 144.6, 141.8, 138.8, 137.2, 135.1, 129.8, 128.4, 126.5, 117.2, 116.6, 116.1, 114.9. ^{11}B NMR (160 MHz, acetone) δ -1.39. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{BBrN}_2$ [M+H]⁺: 413.0819, found 413.0813.




f|1,5,2]diazaborinin-8-amine, 14. The General procedure A was followed by using *N¹,N¹*-diphenyl-*N*⁴-(pyridin-2-yl)benzene-1,4-diamine (67, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), $i\text{Pr}_2\text{NEt}$ (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 45 mg of the product as a yellow solid (45%).


mp 236-237 °C. ^1H NMR (500 MHz, acetone) δ 9.62 (s, 1H), 7.84 – 7.80 (m, 1H), 7.64 (d, J = 5.8 Hz, 1H), 7.21-7.17 (m, 5H), 7.13-7.09 (m, 4H), 7.08 – 7.02 (m, 6H), 6.98-6.96 (m, 5H), 6.91-6.81 (m, 4H), 6.73 (dd, J = 8.3, 2.4 Hz, 1H). ^{13}C NMR (126 MHz, acetone) δ 152.6, 149.6, 144.6, 144.2, 141.4, 136.2, 135.1, 132.7, 130.3, 128.3, 126.3, 124.9, 124.0, 122.9, 115.6, 115.5, 114.8. ^{11}B NMR (160 MHz, acetone) δ -1.34. HRMS (ESI) m/z calcd for C₃₅H₂₈BN₃ [M+H]⁺: 502.2449, found 502.2449.




6,6,8-triphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 15. The General procedure A was followed by using *N*-([1,1'-biphenyl]-4-yl)pyridin-2-amine (49 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 45 mg of the product as a white solid (55%). mp 269-270 °C. ^1H NMR (500 MHz, acetone, CS₂) δ 9.74 (s, 1H), 7.84-7.80 (m, 1H), 7.75 (dd, J = 6.3, 1.4 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.37 – 7.27 (m, 4H), 7.26 – 7.11 (m, 10H), 7.10 – 7.03 (m, 2H), 6.96 – 6.91 (m, 1H), 6.91 – 6.85 (m, 1H). ^{13}C NMR (126 MHz, acetone, CS₂) δ 152.6, 144.7, 143.3, 141.4, 139.3, 136.9, 135.3, 133.7, 130.0, 128.3, 127.8, 127.7, 126.4, 125.8, 115.7, 115.0, 114.9. ^{11}B NMR (160 MHz, acetone, CS₂) δ -1.05. HRMS (ESI) m/z calcd for C₂₉H₂₄BN₂ [M+H]⁺: 411.2027, found 411.2026.




6,6,12,12-tetraphenyl-12,14-dihydro-6H-5l4,6l4-fluoreno[3,2-c]pyrido[2,1-f][1,5,2]diazaborinine, 16. The General procedure A was followed by using *N*-(9,9-diphenyl-9H-fluoren-2-yl)pyridin-2-amine (82 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 34 mg of the product as a light yellow solid (49%). mp >295 °C. ^1H NMR (500 MHz, acetone, CS₂) δ 9.48 (s, 1H), 7.70-7.65 (m, 2H), 7.50 (d, J = 7.6 Hz, 1H), 7.43 (s, 1H), 7.30 – 6.96 (m, 24H), 6.78 – 6.70 (m, 2H). ^{13}C NMR (126 MHz, acetone, CS₂) δ 153.7, 153.2, 151.9, 149.3, 146.3, 144.0, 142.0, 140.9, 138.1, 136.9, 131.0, 130.9, 130.3, 130.0, 129.3, 128.9, 128.7, 128.5, 128.0, 122.4, 116.7, 116.2, 113.8, 67.8. ^{11}B NMR (160 MHz, acetone, CS₂) δ -1.18. HRMS (ESI) m/z calcd for C₄₂H₃₂BN₂ [M+H]⁺: 575.2653, found 575.2655.



7,7-diphenyl-7,13-dihydro-7H,8H-naphtho[2,1-c]pyrido[2,1-f][1,5,2]diazaborinine, 17. The General procedure A was followed by using *N*-(naphthalen-1-yl)pyridin-2-amine (44 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl, 3.6 equiv) and toluene (1 mL) to afford 61 mg of the product as a light yellow solid (80%). mp 229-230 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.92 (dd, *J* = 6.2, 1.2 Hz, 1H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.70 – 7.62 (m, 2H), 7.58 (t, *J* = 7.8 Hz, 1H), 7.53 (d, *J* = 8.2 Hz, 1H), 7.50 – 7.44 (m, 1H), 7.41 (dd, *J* = 11.0, 3.9 Hz, 1H), 7.32 (d, *J* = 8.1 Hz, 1H), 7.26 – 7.13 (m, 10H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.75 (t, *J* = 6.7 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 150.4, 143.9, 139.6, 134.0, 132.7, 132.3, 130.6, 129.0, 127.1, 125.5, 125.3, 124.6, 123.2, 120.7, 117.5, 114.9, 113.3. ¹¹B NMR (160 MHz, CDCl₃) δ -0.74. HRMS (ESI) m/z calcd for C₂₇H₂₂BN₂ [M+H]⁺: 385.1871, found 385.1875.




7,7-diphenyl-4,5,7,13-tetrahydro-7H,8H-acenaphtho[4,5-c]pyrido[2,1-f][1,5,2]diazaborinine, 18. The General procedure A was followed by using *N*-(1,2-dihydroacenaphthylen-5-yl)pyridin-2-amine (49 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl, 3.6 equiv) and toluene (1 mL) to afford 67 mg of the product as a yellow solid (82%). mp 169-171 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 9.49 (s, 1H), 7.85 (d, *J* = 8.4 Hz, 1H), 7.81-7.78 (m, 2H), 7.47 (d, *J* = 8.9 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.18-7.10 (m, 9H), 7.05-7.02 (m, 2H), 6.98 (s, 1H), 6.86 (t, *J* = 6.5 Hz, 1H), 3.37 – 3.30 (m, 2H), 3.26 – 3.20 (m, 2H). ¹³C NMR (126 MHz, acetone, CS₂) δ 153.0, 147.9, 145.1, 141.3, 141.2, 140.4, 135.9, 130.3, 128.9, 128.8, 127.2, 126.7, 122.0, 120.0, 117.1, 116.1, 115.7, 32.4, 31.5. ¹¹B NMR (160 MHz, acetone, CS₂) δ -0.96. HRMS (ESI) m/z calcd for C₂₉H₂₄¹⁰BN₂ [M+H]⁺: 410.2063, found 410.2061.




7,7-diphenyl-7,13-dihydro-7l4,8l4-pyreno[2,1-c]pyrido[2,1-f][1,5,2]diazaborinine, 19.

The General procedure A was followed by using *N*-(pyren-1-yl)pyridin-2-amine (59 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 30 mg of the product as a yellow solid (33%). mp 270-272 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 9.84 (s, 1H), 8.38 (d, *J* = 9.3 Hz, 1H), 8.05 – 7.94 (m, 3H), 7.91 – 7.75 (m, 6H), 7.62 (d, *J* = 8.6 Hz, 1H), 7.15 – 6.97 (m, 10H), 6.95 – 6.87 (m, 1H). ¹³C NMR (126 MHz, acetone, CS₂) δ 154.3, 146.6, 142.5, 137.3, 135.3, 135.0, 134.7, 133.9, 131.3, 130.4, 130.2, 129.6, 128.6, 128.5, 128.3, 127.7, 127.5, 127.1, 126.7, 122.7, 118.5, 117.9, 117.4. ¹¹B NMR (160 MHz, acetone, CS₂) δ -0.66. HRMS (ESI) m/z calcd for C₃₃H₂₄BN₂ [M+H]⁺: 459.2027, found 459.2028.




11-methyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 20.

The General procedure A was followed by using *N*-methyl-*N*-phenylpyridin-2-amine (37 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 20 mg of the product as a white solid (29%). mp 227-228 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 8.04-8.00 (M, 1H), 7.87 (dd, *J* = 6.2, 1.6 Hz, 1H), 7.38 (d, *J* = 8.8 Hz, 1H), 7.22 – 7.15 (m, 1H), 7.12 – 7.07 (m, 4H), 7.07 – 7.02 (m, 4H), 7.01 – 6.98 (m, 2H), 6.97 – 6.93 (m, 4H), 3.52 (s, 3H). ¹³C NMR (126 MHz, acetone, CS₂) δ 154.4, 145.7, 144.2, 142.6, 135.8, 135.5, 128.7, 127.7, 126.8, 124.9, 116.4, 114.5, 114.2, 37.5. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.23. HRMS (ESI) m/z calcd for C₂₄H₂₂BN₂ [M+H]⁺: 349.1871, found 349.1872.




6,6,8-triphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 21. The General procedure A was followed by using 3-methyl-*N*-phenylpyridin-2-amine (37 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 39 mg of the product as a white

solid (56%). mp 260-262 °C. ^1H NMR (500 MHz, acetone) δ 8.54 (s, 1H), 7.70 (dd, J = 11.7, 6.7 Hz, 2H), 7.14 – 7.03 (m, 12H), 7.00 (d, J = 7.1 Hz, 1H), 6.96 – 6.90 (m, 1H), 6.83 (t, J = 6.7 Hz, 1H), 2.44 (s, 3H). ^{13}C NMR (126 MHz, acetone) δ 151.4, 142.7, 141.2, 139.7, 135.2, 135.0, 128.1, 126.9, 126.2, 124.4, 122.7, 115.2, 115.1, 17.9. ^{11}B NMR (160 MHz, acetone) δ -1.08. HRMS (ESI) m/z calcd for C₂₄H₂₂BN₂ [M+H]⁺: 349.1871, found 349.1866.




2-methyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 22.

The General procedure A was followed by using 4-methyl-N-phenylpyridin-2-amine (37 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μ l, 1 equiv), iPr₂NEt (0.72 mmol, 119 μ l, 3.6 equiv) and toluene (1 mL) to afford 40 mg of the product as a white solid (57%). mp 260-262 °C. ^1H NMR (500 MHz, acetone) δ 9.38 (s, 1H), 7.61 (d, J = 6.5 Hz, 1H), 7.16 – 7.08 (m, 8H), 7.07-7.00 (m, 4H), 6.94 (s, 1H), 6.91-6.88 (m, 1H), 6.81 (d, J = 7.6 Hz, 1H), 6.71 (dd, J = 6.5, 1.6 Hz, 1H), 2.35 (s, 3H). ^{13}C NMR (126 MHz, acetone) δ 153.3, 152.4, 144.0, 139.7, 135.2, 135.1, 128.1, 126.9, 126.1, 124.1, 117.3, 114.2, 113.7, 21.7. ^{11}B NMR (160 MHz, acetone) δ -1.55. HRMS (ESI) m/z calcd for C₂₄H₂₂BN₂ [M+H]⁺: 349.1871, found 349.1869.




3-methyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 23. The General procedure A was followed by using 5-methyl-N-phenylpyridin-2-amine (37 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μ l, 1 equiv), iPr₂NEt (0.72 mmol, 119 μ l, 3.6 equiv) and toluene (1 mL) to afford 38 mg of the product as a white solid (54%). mp 256-257 °C. ^1H NMR (500 MHz, acetone) δ 9.41 (s, 1H), 7.66 (dd, J = 8.8, 2.1 Hz, 1H), 7.58 (s, 1H), 7.17 – 7.09 (m, 9H), 7.08 – 6.97 (m, 4H), 6.88 (td, J = 7.3, 1.0 Hz, 1H), 6.80 (d, J = 7.9 Hz, 1H), 2.11 (s, 3H). ^{13}C NMR (126 MHz, acetone) δ 151.1, 143.0, 142.8, 139.7, 135.2, 135.1, 128.1, 126.0, 126.1, 124.8, 124.0, 114.5, 114.1, 18.0. ^{11}B NMR (160 MHz, acetone) δ -1.29. HRMS (ESI) m/z calcd for C₂₄H₂₂BN₂ [M+H]⁺: 349.1871, found 349.1870.




3-methoxy-6,6-diphenyl-6,11-dihydro-5*I*4,6*I*4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 24.


The General procedure A was followed by using 5-methoxy-*N*-phenylpyridin-2-amine (40 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 18 mg of the product as a white solid (25%). mp 243-244 °C. ¹H NMR (500 MHz, acetone) δ 9.34 (s, 1H), 7.61 (dd, *J* = 9.3, 2.9 Hz, 1H), 7.36 (d, *J* = 2.9 Hz, 1H), 7.20 – 7.10 (m, 9H), 7.09 – 6.99 (m, 4H), 6.94 – 6.85 (m, 1H), 6.79 (dd, *J* = 8.3, 0.9 Hz, 1H), 3.60 (s, 3H). ¹³C NMR (126 MHz, acetone) δ 150.4, 148.5, 140.1, 135.2, 135.1, 131.9, 128.2, 127.9, 127.0, 126.2, 123.9, 115.8, 114.1, 57.0. ¹¹B NMR (160 MHz, acetone) δ -0.80 (s). HRMS (ESI) m/z calcd for C₂₄H₂₂¹⁰BN₂O [M+H]⁺: 364.1856, found 364.1857.

**3-chloro-6,6-diphenyl-6,11-dihydro-5*I*4,6*I*4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 25.**


The General procedure A was followed by using 5-chloro-*N*-phenylpyridin-2-amine (40 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (89 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 34 mg of the product as a yellow solid (46%). mp 232-233 °C. ¹H NMR (500 MHz, acetone) δ 9.80 (s, 1H), 7.83 (dd, *J* = 9.2, 2.5 Hz, 1H), 7.70 (d, *J* = 2.5 Hz, 1H), 7.23 (d, *J* = 9.2 Hz, 1H), 7.20 – 7.14 (m, 4H), 7.14 – 7.04 (m, 7H), 7.01 (dd, *J* = 7.3, 1.4 Hz, 1H), 6.95 (td, *J* = 7.3, 1.0 Hz, 1H), 6.86 (d, *J* = 7.9 Hz, 1H). ¹³C NMR (126 MHz, acetone) δ 151.5, 142.0, 141.5, 139.1, 135.2, 135.1, 128.4, 127.2, 126.5, 124.9, 121.6, 116.6, 114.7. ¹¹B NMR (160 MHz, acetone) δ -0.65. HRMS (ESI) m/z calcd for C₂₃H₁₉BClN₂ [M+H]⁺: 369.1324, found 369.1323.

**4,4-diphenyl-4*H*-4*I*4,5*I*4-pyrrolo[2',1':3,4][1,4,2]diazaborolo[1,5-a]pyridine, 26.** The General procedure B was followed by using 2-(1*H*-pyrrol-1-yl)pyridine (29 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (133 mg 0.72 mmol, 3.6 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (1 mmol, 165 µl, 5 equiv) and toluene (1 mL) to afford 40 mg of the product as a white solid (66%). mp 251-253 °C. ¹H NMR (500 MHz, Acetone, CS₂) δ 8.48 – 8.41 (m, 1H), 8.21-8.17 (m, 1H), 7.88 – 7.78 (m, 1H), 7.45 (dd, *J* = 2.9, 0.9 Hz, 1H), 7.35-7.32 (m, 1H), 7.29-7.28 (m, 4H), 7.21 – 7.12 (m, 4H), 7.11 – 7.04 (m, 2H), 6.47 (t, *J* = 2.9 Hz, 1H), 6.19 (dd, *J* = 3.0, 0.9 Hz, 1H). ¹³C NMR (126 MHz, Acetone, CS₂) δ 151.5, 145.2, 144.9, 134.4, 128.7, 127.1, 120.3, 118.7, 113.7,


112.1, 110.9. ^{11}B NMR (160 MHz, Acetone, CS₂) δ 0.7. HRMS (ESI) m/z calcd for C₂₁H₁₈BN₂ [M+H]⁺: 309.1558, found 309.1557.



9,9-diphenyl-9H,9l4-thieno[2',3':3,4][1,2]azaborolo[1,5-a]pyridine, 27. The General procedure B was followed by using 2-(thiophen-3-yl)pyridine (32 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (133 mg 0.72 mmol, 3.6 equiv), SiCl₄ (0.2 mmol, 24 μl , 1 equiv), iPr₂NEt (1 mmol, 165 μl , 5 equiv) and toluene (1 mL) to afford 27 mg of the product as a white solid (42%). mp 158–159 °C. ^1H NMR (500 MHz, Acetone) δ 8.58 (d, J = 5.8 Hz, 1H), 8.23 (td, J = 8.0, 1.4 Hz, 1H), 8.10 – 8.03 (m, 1H), 7.64–7.61 (m, 2H), 7.49–7.46 (m, 1H), 7.22–7.20 (m, 4H), 7.18 – 7.12 (m, 4H), 7.12 – 7.07 (m, 2H). ^{13}C NMR (126 MHz, Acetone) δ 155.7, 146.2, 143.4, 141.9, 134.1, 132.7, 128.7, 127.0, 121.7, 121.5, 119.5. ^{11}B NMR (160 MHz, Acetone) δ 3.06. HRMS (ESI) m/z calcd for C₂₁H₁₇BNS [M+H]⁺: 326.1169, found 326.1171.




11-methyl-6,6-diphenyl-6,11-dihydro-5l4,6l4-pyrido[1',2':1,5][1,2]azaborolo[4,3-b]indole, 28. The General procedure B was followed by using 1-methyl-2-(pyridin-2-yl)-1H-indole (41 mg, 0.2 mmol, 1 equiv), potassium phenyltrifluoroborate (133 mg 0.72 mmol, 3.6 equiv), SiCl₄ (0.2 mmol, 24 μl , 1 equiv), iPr₂NEt (1 mmol, 165 μl , 5 equiv) and toluene (1 mL) to afford 54 mg of the product as a yellow solid (72%). mp 247–249 °C. ^1H NMR (500 MHz, Acetone, CS₂) δ 8.50 (d, J = 5.7 Hz, 1H), 8.08 (t, J = 7.8 Hz, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.33–7.27 (m, 2H), 7.24 – 7.15 (m, 5H), 7.07–7.03 (m, 4H), 7.03 – 6.95 (m, 3H), 4.12 (s, 3H). ^{13}C NMR (126 MHz, Acetone, CS₂) δ 153.9, 148.4, 147.0, 143.7, 140.5, 136.3, 131.7, 130.3, 128.4, 127.3, 127.2, 122.6, 121.9, 119.6, 112.8, 33.9. ^{11}B NMR (160 MHz, Acetone, CS₂) δ 2.31. HRMS (ESI) m/z calcd for C₂₆H₂₁BKN₂ [M+K]⁺: 411.1429, found 411.1432.




4-methyl-6,6-diphenyl-4,6-dihydro-6l4,7l4-pyrido[1',2':1,6][1,2]azaborinino[3,4,5-cd]indole, 29. The General procedure B was followed by using 1-methyl-4-(pyridin-2-yl)-1H-indole (41 mg, 0.2

mmol, 1 equiv), potassium phenyltrifluoroborate (133 mg 0.72 mmol, 3.6 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), iPr₂NEt (1 mmol, 165 µl, 5 equiv) and toluene (1 mL) to afford 52 mg of the product as a yellow solid (70%). mp 235-237 °C. ¹H NMR (500 MHz, Acetone, CS₂) δ 8.60 (dd, *J* = 9.6, 4.6 Hz, 2H), 8.16-8.12 (m, 1H), 7.81 (d, *J* = 7.5 Hz, 1H), 7.49 – 7.40 (m, 2H), 7.24-7.20 (m, 5H), 7.11-7.08 (m, 4H), 7.05 – 6.97 (m, 2H), 6.81 (s, 1H), 3.80 (s, 3H). ¹³C NMR (126 MHz, Acetone, CS₂) δ 154.8, 150.9, 141.9, 138.4, 135.4, 132.5, 131.3, 128.5, 126.4, 123.9, 123.4, 123.1, 122.7, 116.5, 114.1, 33.6. ¹¹B NMR (160 MHz, Acetone, CS₂) δ 2.75. HRMS (ESI) m/z calcd for C₂₆H₂₂BN₂ [M+H]⁺: 373.1871, found 373.1872.



Me 6,6-di-p-tolyl-6,11-dihydro-5H,6H-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 30.


The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium *p*-tolyltrifluoroborate (95 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), iPr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 51 mg of the product as a white solid (70%). mp 289-290 °C. ¹H NMR (500 MHz, acetone) δ 9.50 (s, 1H), 7.78-7.75 (m, 2H), 7.13 (dd, *J* = 9.2, 1.0 Hz, 1H), 7.05 – 6.98 (m, 6H), 6.95 (d, *J* = 7.7 Hz, 4H), 6.92 – 6.87 (m, 1H), 6.86 – 6.79 (m, 2H), 2.23 (s, 6H). ¹³C NMR (126 MHz, acetone) δ 152.6, 144.6, 141.2, 139.5, 135.2, 135.1, 134.9, 128.9, 126.8, 124.2, 115.3, 114.6, 114.2, 21.7. ¹¹B NMR (160 MHz, acetone) δ -1.23. HRMS (ESI) m/z calcd for C₂₅H₂₄BN₂ [M+H]⁺: 363.2027, found 363.2028.



iPr 6,6-bis(4-isopropylphenyl)-6,11-dihydro-5H,6H-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 31.


The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-isopropylphenyltrifluoroborate (108 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), iPr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 57 mg of the product as a white solid (68%). mp 257-258 °C. ¹H NMR (500 MHz, acetone) δ 9.49 (s, 1H), 7.83 – 7.73 (m, 2H), 7.13 (dd, *J* = 9.3, 1.2 Hz, 1H), 7.07 – 6.99 (m, 10H), 6.93 – 6.86 (m, 1H), 6.86 – 6.78 (m, 2H), 2.85-2.77 (m, 2H), 1.20 (d, *J* = 6.9 Hz, 12H). ¹³C NMR (126 MHz, acetone) δ 152.6, 146.1, 144.8, 141.2, 139.5, 135.3, 126.8, 126.2, 124.2, 115.4, 114.6,

114.3, 35.0, 25.0, 25.0. ^{11}B NMR (160 MHz, acetone) δ -1.18. HRMS (ESI) m/z calcd for C₂₉H₃₂BN₂ [M+H]⁺: 419.2653, found 419.2654.




6,6-bis(4-fluorophenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 32.

The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-fluorophenyltrifluoroborate (97 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 34 mg of the product as a white solid (46%). mp 213-214 °C. ^1H NMR (500 MHz, acetone) δ 9.62 (s, 1H), 7.86 – 7.77 (m, 1H), 7.74 (d, J = 6.3 Hz, 1H), 7.18 (d, J = 8.7 Hz, 1H), 7.09-7.05 (m, 5H), 6.98 – 6.84 (m, 8H). ^{13}C NMR (126 MHz, acetone) δ 162.7 (d, J = 240 Hz), 152.6, 144.3, 141.5, 139.5, 136.6 (d, J = 6.8 Hz), 135.0, 127.2, 124.5, 115.8, 114.9, 114.7 (d, J = 18.7 Hz), 114.5. ^{11}B NMR (160 MHz, acetone) δ -1.67. HRMS (ESI) m/z calcd for C₂₃H₁₈BF₂N₂ [M+H]⁺: 371.1526, found 371.1526.




6,6-bis(4-chlorophenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 33.


The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-chlorophenyltrifluoroborate (104 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 μl , 1 equiv), *iPr*₂NEt (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 38 mg of the product as a white solid (47%). mp 280-281 °C. ^1H NMR (500 MHz, acetone) δ 9.66 (s, 1H), 7.84-7.80 (m, 1H), 7.77 – 7.70 (m, 1H), 7.24 – 7.14 (m, 5H), 7.13 – 7.01 (m, 5H), 7.00 – 6.84 (m, 4H). ^{13}C NMR (126 MHz, acetone) δ 152.5, 144.2, 141.6, 139.4, 136.7, 134.8, 131.9, 128.2, 127.3, 124.5, 115.8, 114.9, 114.54. ^{11}B NMR (160 MHz, acetone) δ -1.74. HRMS (ESI) m/z calcd for C₂₃H₁₇BCl₂N₂Na [M+Na]⁺: 425.0754, found 425.0762.



6,6-bis(4-bromophenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 34. The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-bromophenyltrifluoroborate (126 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 42 mg of the product as a white solid (43%). mp 283-284 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 9.64 (s, 1H), 7.84-7.81 (m, 1H), 7.72 (d, *J* = 5.3 Hz, 1H), 7.31 (d, *J* = 8.2 Hz, 4H), 7.18 (d, *J* = 8.6 Hz, 1H), 7.10 – 7.03 (m, 1H), 7.02 (d, *J* = 8.2 Hz, 4H), 6.98 – 6.82 (m, 4H). ¹³C NMR (126 MHz, acetone, CS₂) δ 152.6, 144.3, 141.7, 139.5, 137.3, 135.0, 131.3, 127.5, 124.7, 120.6, 116.0, 115.1, 114.7. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.76. HRMS (ESI) m/z calcd for C₂₃H₁₈BB₂N₂ [M+H]⁺: 490.9924, found 490.9920.




6,6-di(naphthalen-2-yl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 35. The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium naphthalen-2-yltrifluoroborate (112 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 60 mg of the product as a white solid (69%). mp 164-165 °C. ¹H NMR (500 MHz, acetone) δ 9.65 (s, 1H), 7.87 (dd, *J* = 6.4, 1.4 Hz, 1H), 7.83 – 7.74 (m, 3H), 7.71 (d, *J* = 8.3 Hz, 2H), 7.65 – 7.57 (m, 2H), 7.54 – 7.46 (m, 4H), 7.41 – 7.28 (m, 4H), 7.22 (d, *J* = 8.6 Hz, 1H), 7.15 – 7.04 (m, 2H), 6.96 (td, *J* = 7.3, 1.0 Hz, 1H), 6.92 – 6.81 (m, 2H). ¹³C NMR (126 MHz, acetone) δ 152.7, 144.7, 141.5, 139.7, 135.2, 134.8, 134.0, 133.9, 133.7, 128.9, 128.6, 127.2, 127.1, 126.2, 125.8, 124.5, 115.7, 114.8, 114.5. ¹¹B NMR (160 MHz, acetone) δ -1.03. HRMS (ESI) m/z calcd for C₃₁H₂₄BN₂ [M+H]⁺: 435.2027, found 435.2029.




6,6-di(thiophen-3-yl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 36.

The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium thiophen-3-yltrifluoroborate (91 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 28 mg of the product as a white solid (40%). mp 264-265 °C. ¹H NMR (500 MHz, acetone) δ 9.57 (s, 1H), 7.84 (d, *J* = 6.3 Hz, 1H), 7.80-7.77 (m, 1H), 7.25-7.24 (m, 2H), 7.13 (d, *J* = 8.6 Hz, 1H), 7.07 – 7.00 (m, 2H), 6.96 – 6.81 (m, 5H), 6.76-6.73 (m, 2H). ¹³C NMR (126 MHz, acetone) δ 152.2, 144.3, 141.4, 139.0, 134.7, 134.1, 127.3, 127.1, 125.0, 124.3, 115.6, 114.7, 114.5. ¹¹B NMR (160 MHz, acetone) δ -4.24. HRMS (ESI) m/z calcd for C₁₉H₁₆BN₂S₂ [M+H]⁺: 347.0842, found 347.0844.



6,6-di(thiophen-2-yl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 37.


The General procedure A was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium thiophen-2-yltrifluoroborate (91 mg 0.48 mmol, 2.4 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 14 mg of the product as a white solid (19%). mp 226-227 °C. ¹H NMR (500 MHz, acetone) δ 9.70 (s, 1H), 8.01 – 7.93 (m, 1H), 7.81-7.78 (m, 1H), 7.34 (dd, *J* = 4.8, 0.9 Hz, 2H), 7.22 – 7.03 (m, 3H), 7.01 – 6.84 (m, 5H), 6.82 (d, *J* = 3.2 Hz, 2H). ¹³C NMR (126 MHz, acetone) δ 151.7, 144.2, 141.7, 138.7, 135.4, 131.7, 128.1, 127.7, 127.6, 124.4, 115.7, 114.8, 114.6. ¹¹B NMR (160 MHz, acetone) δ -4.61. HRMS (ESI) m/z calcd for C₁₉H₁₆BN₂S₂ [M+H]⁺: 347.0842, found 347.0842.




6-(3,5-bis(trifluoromethyl)phenyl)-6-(4-methoxyphenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 38.

The General procedure C was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-

methoxyphenyltrifluoroborate (51 mg 0.24 mmol, 1.2 equiv), potassium 3,5-bis(trifluoromethyl)trifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), $i\text{Pr}_2\text{NEt}$ (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 37 mg of the product as a white solid (37%). mp 221-222 $^{\circ}\text{C}$. ^1H NMR (500 MHz, acetone) δ 9.76 (s, 1H), 7.90-7.86 (m, 1H), 7.79 (d, J = 6.4 Hz, 1H), 7.70 (s, 1H), 7.60 (s, 2H), 7.24 (d, J = 8.7 Hz, 1H), 7.12-7.09 (m, 1H), 7.06-6.93 (m, 6H), 6.90 (d, J = 7.8 Hz, 1H), 6.83 – 6.77 (m, 2H), 3.74 (s, 3H). ^{13}C NMR (126 MHz, acetone) δ 159.5, 152.6, 144.0, 141.9, 139.5, 136.5, 134.7, 134.3, 130.6(q, J = 31.3 Hz), 127.7, 125.7(q, J = 270.0 Hz), 124.7, 119.9 (q, J = 3.7 Hz), 116.1, 115.2, 114.5, 114.3, 55.6. ^{11}B NMR (160 MHz, acetone) δ -1.66. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{19}\text{BF}_6\text{N}_2\text{NaO} [\text{M}+\text{Na}]^+$: 523.1387, found 523.1378.




The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-methoxyphenyltrifluoroborate (51 mg 0.24 mmol, 1.2 equiv), potassium 4-(trifluoromethyl)phenyltrifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl_4 (0.2 mmol, 24 μl , 1 equiv), $i\text{Pr}_2\text{NEt}$ (0.72 mmol, 119 μl , 3.6 equiv) and toluene (1 mL) to afford 40 mg of the product as a white solid (46%) with 9% isomer. mp 248-250 $^{\circ}\text{C}$. ^1H NMR (500 MHz, acetone) δ 9.63 (s, 1H), 7.84-7.80 (m, 1H), 7.75 (dd, J = 6.4, 1.5 Hz, 1H), 7.44 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 7.7 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1H), 7.07 – 7.03 (m, 3H), 7.01 (dd, J = 7.4, 1.4 Hz, 1H), 6.95 (dd, J = 7.3, 1.0 Hz, 1H), 6.91 (ddd, J = 13.4, 6.1, 1.1 Hz, 1H), 6.86 (dd, J = 7.8, 0.5 Hz, 1H), 6.79 – 6.76 (m, 2H), 3.73 (s, 3H). ^{13}C NMR (126 MHz, acetone) δ 159.3, 152.6, 144.3, 141.5, 139.5, 136.6, 135.0, 134.8, 127.6 (q, J = 31.3 Hz), 127.2, 124.5 (q, J = 3.6 Hz), 124.4, 115.7, 114.8, 114.5, 114.0, 55.5. ^{11}B NMR (160 MHz, acetone) δ -1.53. HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{20}\text{BF}_3\text{N}_2\text{NaO} [\text{M}+\text{Na}]^+$: 455.1513, found 455.1521.




6-(4-methoxyphenyl)-6-(3,4,5-trifluorophenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 40.

The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 4-methoxyphenyltrifluoroborate (51 mg 0.24 mmol, 1.2 equiv), potassium 3,4,5-trifluorophenyltrifluoroborate (57 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 34 mg of the product as a white solid (41%). mp 202–204 °C. ¹H NMR (500 MHz, acetone) δ 9.71 (s, 1H), 7.86–7.83 (m, 1H), 7.80 – 7.74 (m, 1H), 7.20 (d, *J* = 8.6 Hz, 1H), 7.09 (ddd, *J* = 7.9, 6.9, 2.1 Hz, 1H), 7.05 – 6.91 (m, 6H), 6.88 (d, *J* = 7.8 Hz, 1H), 6.81 – 6.76 (m, 2H), 6.68 (dd, *J* = 9.3, 7.4 Hz, 2H), 3.73 (s, 3H). ¹³C NMR (126 MHz, acetone) δ 159.4, 152.5, 151.6 (ddd, *J* = 246.3, 8.7, 2.5 Hz), 144.1, 141.6, 139.4, 138.1 (dt, *J* = 276.3, 15.8 Hz), 136.3, 134.8, 127.5, 124.5, 117.3 (dd, *J* = 13.3, 3.0 Hz), 115.9, 114.9, 114.6, 114.1, 55.5. ¹¹B NMR (160 MHz, acetone) δ -1.97. HRMS (ESI) m/z calcd for C₂₄H₁₈BF₃N₂NaO [M+Na]⁺: 441.1356, found 441.1359.




6-(3,5-bis(trifluoromethyl)phenyl)-6-(3,5-dimethylphenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 41.

The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium 3,5-dimethylphenyltrifluoroborate (51 mg 0.24 mmol, 1.2 equiv), potassium 3,5-bis(trifluoromethyl)trifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 45 mg of the product as a white solid (45%) with 9% isomer. mp 197–198 °C. ¹H NMR (500 MHz, acetone) δ 9.72 (s, 1H), 7.90–7.87 (m, 1H), 7.78 (d, *J* = 6.3 Hz, 1H), 7.70 (s, 1H), 7.61 (s, 2H), 7.23 (d, *J* = 8.7 Hz, 1H), 7.12 – 7.06 (m, 1H), 7.00 – 6.93 (m, 3H), 6.89 (d, *J* = 7.8 Hz, 1H), 6.79 (s, 1H), 6.74 (s, 2H), 2.16 (s, 6H). ¹³C NMR (126 MHz, acetone) δ 152.7, 144.2, 141.9, 139.5, 137.3, 134.8, 134.6, 133.4, 133.3, 130.6 (q, *J* = 31.3 Hz), 128.7, 127.7, 125.7 (q, *J* = 270.0 Hz), 124.8, 120.0 (q, *J* = 3.6 Hz), 116.1, 115.2, 114.8, 22.2. ¹¹B NMR (160 MHz, acetone) δ -1.74. HRMS (ESI) m/z calcd for C₂₇H₂₀BF₆N₂ [M-H⁺]: 497.1629, found 497.1637.




6-(thiophen-2-yl)-6-(4-(trifluoromethyl)phenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 42.

The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium thiophen-2-yltrifluoroborate (46 mg 0.24 mmol, 1.2 equiv), potassium 4-(trifluoromethyl)phenyltrifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 26 mg of the product as a white solid (32%). mp 212-214 °C. ¹H NMR (500 MHz, DMSO) δ 10.60 (s, 1H), 7.88 – 7.79 (m, 1H), 7.68 (d, *J* = 6.3 Hz, 1H), 7.47 (d, *J* = 8.1 Hz, 2H), 7.44 (d, *J* = 4.7 Hz, 1H), 7.23 (d, *J* = 7.9 Hz, 2H), 7.14 (d, *J* = 8.7 Hz, 1H), 7.08 (td, *J* = 7.6, 1.5 Hz, 1H), 7.00 (dd, *J* = 4.7, 3.3 Hz, 1H), 6.98 – 6.94 (m, 1H), 6.92-6.85 (m, 3H), 6.66 (d, *J* = 3.2 Hz, 1H). ¹³C NMR (126 MHz, DMSO) δ 150.2, 142.3, 140.5, 137.2, 133.2, 132.9, 130.7, 127.3, 126.2, 125.7(q, *J* = 31.3), 123.4 (q, *J* = 3.7 Hz), 122.9, 114.5, 113.7, 113.4. ¹¹B NMR (160 MHz, DMSO) δ -3.37. HRMS (ESI) m/z calcd for C₂₂H₁₇BF₃N₂S [M+H]⁺: 409.1152, found 409.1158.




6-(benzo[b]thiophen-2-yl)-6-(3,5-bis(trifluoromethyl)phenyl)-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 43.

The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium benzo[b]thiophen-2-yltrifluoroborate (58 mg 0.24 mmol, 1.2 equiv), potassium 3,5-bis(trifluoromethyl)trifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 45 mg of the product as a white solid (43%). mp 192-194 °C. ¹H NMR (500 MHz, acetone) ¹H NMR (500 MHz, Acetone) δ 9.88 (s, 1H), 8.00 – 7.90 (m, 2H), 7.81-7.76 (m, 4H), 7.68 (d, *J* = 7.8 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.22 – 7.18 (m, 1H), 7.16 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.12 (d, *J* = 7.4 Hz, 1H), 7.06 – 6.99 (m, 2H), 6.96 – 6.90 (m, 2H). ¹³C NMR (126 MHz, Acetone) δ 152.4, 144.4, 143.9, 143.1, 142.3, 139.1, 134.9, 134.4, 130.8(q, *J* = 31.3 Hz), 129.5, 128.3, 125.7 (q, *J* = 270.0 Hz), 125.0, 124.8, 124.30, 124.1, 123.3, 120.6 (q, *J* = 3.6 Hz), 116.5, 115.5, 115.1. ¹¹B NMR (160 MHz, acetone) δ -3.40. HRMS (ESI) m/z calcd for C₂₇H₁₇BF₆N₂NaS [M+Na]⁺: 549.1002, found 549.1009.




6-(3,5-bis(trifluoromethyl)phenyl)-6-(furan-2-yl)-6,11-dihydro-5l4,6l4-

benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 44. The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium furan-2-yltrifluoroborate (42 mg 0.24 mmol, 1.2 equiv), potassium 3,5-bis(trifluoromethyl)trifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 μ l, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 μ l, 3.6 equiv) and toluene (1 mL) to afford 25 mg of the product as a white solid (27 %). mp 232–234 °C. ¹H NMR (500 MHz, acetone) δ 9.79 (s, 1H), 7.92 – 7.83 (m, 2H), 7.71 (s, 1H), 7.68 (s, 2H), 7.62 – 7.56 (m, 1H), 7.22 (d, *J* = 8.6 Hz, 1H), 7.11 (td, *J* = 7.8, 1.6 Hz, 1H), 7.07 – 7.00 (m, 1H), 6.97 (dtd, *J* = 10.7, 7.1, 1.1 Hz, 2H), 6.91 (d, *J* = 7.9 Hz, 1H), 6.31 (dd, *J* = 3.1, 1.7 Hz, 1H), 6.03 (d, *J* = 3.1 Hz, 1H). ¹³C NMR (126 MHz, acetone) δ 152.1, 145.3, 144.2, 142.1, 138.9, 134.7, 134.0, 131.1, 130.7 (q, *J* = 31.3 Hz), 128.0, 126.7 (q, *J* = 270.0 Hz), 124.7, 120.2 (q, *J* = 3.6 Hz), 117.0, 116.1, 115.4, 115.1, 110.5. ¹¹B NMR (160 MHz, acetone) δ -4.61. HRMS (ESI) m/z calcd for C₂₃H₁₅BF₆N₂NaO [M+ Na]⁺: 483.1074, found 483.1077.




6-(benzofuran-2-yl)-6-(3,5-bis(trifluoromethyl)phenyl)-6,11-dihydro-

5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 45. The General procedure **C** was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium benzofuran-2-yltrifluoroborate (54 mg 0.24 mmol, 1.2 equiv), potassium 3,5-bis(trifluoromethyl)trifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 μ l, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 μ l, 3.6 equiv) and toluene (1 mL) to afford 37 mg of the product as a white solid (36%). mp 141–142 °C. ¹H NMR (500 MHz, acetone) δ 9.89 (s, 1H), 7.99 (d, *J* = 6.3 Hz, 1H), 7.92–7.89 (m, 1H), 7.78 (s, 2H), 7.77 (s, 1H), 7.56 – 7.46 (m, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.26 (d, *J* = 8.7 Hz, 1H), 7.20 – 7.06 (m, 4H), 7.05 – 6.91 (m, 3H), 6.41 (s, 1H). ¹³C NMR (126 MHz, acetone) δ 158.9, 152.2, 144.3, 142.3, 138.9, 134.7, 134.2, 131.3, 130.9 (q, *J* = 31.3 Hz), 130.7, 128.3, 125.7 (q, *J* = 270.0 Hz), 124.9, 124.2, 123.1, 121.7, 120.5 (q, *J* = 3.6 Hz), 116.3, 115.5, 115.2, 114.0, 112.0. ¹¹B NMR (160 MHz, acetone) δ -4.66. HRMS (ESI) m/z calcd for C₂₇H₁₆BF₆N₂O [M-H]⁻: 509.1265, found 509.1266.




(*E*)-6-styryl-6-(4-(trifluoromethyl)phenyl)-6,11-dihydro-5H,6H-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 46.

The General procedure C was followed by using *N*-phenylpyridin-2-amine (34 mg, 0.2 mmol, 1 equiv), potassium *E*-styryltrifluoroborate (51 mg 0.24 mmol, 1.2 equiv), potassium 4-(trifluoromethyl)phenyltrifluoroborate (77 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 34 mg of the product as a white solid (40%). mp 201–203 °C. ¹H NMR (500 MHz, acetone) δ 9.62 (s, 1H), 7.92 (d, *J* = 6.3 Hz, 1H), 7.86–7.83 (m, 1H), 7.47 (d, *J* = 8.1 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.36 (d, *J* = 7.3 Hz, 2H), 7.24 (t, *J* = 7.7 Hz, 2H), 7.18 (d, *J* = 8.7 Hz, 1H), 7.15 – 7.01 (m, 4H), 6.97 – 6.89 (m, 2H), 6.86 (d, *J* = 7.9 Hz, 1H), 6.14 (d, *J* = 17.9 Hz, 1H). ¹³C NMR (126 MHz, acetone) δ 152.3, 144.5, 141.6, 141.5, 138.9, 137.0, 134.9, 134.7, 129.6, 127.9 (*d*, *J* = 31.3 Hz), 127.5, 127.3, 127.2, 124.74 (*q*, *J* = 3.7 Hz), 124.5, 115.8, 114.9, 114.8. ¹¹B NMR (160 MHz, acetone) δ -3.23 (s). HRMS (ESI) m/z calcd for C₂₆H₂₁BF₃N₂ [M+H]⁺: 429.1744, found 429.1747.




13H-7H,8H-spiro[benzo[3,4][1,5,2]diazaborinino[6,1-a]isoquinoline-8,5'-dibenzoborole], 47.

The general procedure A was followed by using *N*-phenylisoquinolin-1-amine (44 mg, 0.2 mmol, 1 equiv), 2,2'-bis(trifluoro-1*H*-boranyl)-1,1'-biphenyl, dipotassium salt (88 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 49 mg of the product as a white solid (64%). mp 286–288 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 9.89 (s, 1H), 8.73 (d, *J* = 8.5 Hz, 1H), 7.87 – 7.70 (m, 3H), 7.70 – 7.60 (m, 2H), 7.24 (t, *J* = 8.0 Hz, 3H), 7.16 (td, *J* = 7.5, 1.1 Hz, 2H), 7.06 – 6.93 (m, 4H), 6.90 (d, *J* = 7.0 Hz, 1H), 6.75 (td, *J* = 7.3, 0.9 Hz, 1H), 6.57 (dd, *J* = 7.3, 1.2 Hz, 1H). ¹³C NMR (126 MHz, acetone, CS₂) δ 151.1, 150.3, 140.0, 138.6, 137.3, 134.9, 134.7, 132.9, 130.1, 129.6, 128.6, 128.5, 127.8, 126.1, 125.5, 121.0, 117.0, 114.8. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.87. HRMS (ESI) m/z calcd for C₂₇H₂₀BN₂ [M+H]⁺: 383.1714, found 383.1712.




8-(9H-carbazol-9-yl)-11H-5l4,6l4-spiro[benzo[c]pyrido[2,1-f][1,5,2]diazaborinine-6,5'-dibenzo[b,d]borole], 48.

The general procedure A was followed by using *N*-(4-(9H-carbazol-9-yl)phenyl)pyridin-2-amine (67 mg, 0.2 mmol, 1 equiv), 2,2'-bis(trifluoro-14-boranyl)-1,1'-biphenyl, dipotassium salt (88 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 60 mg of the product as a white solid (60%). mp 109-110 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 9.96 (s, 1H), 8.08 – 7.97 (m, 2H), 7.83 – 7.69 (m, 1H), 7.58 (d, *J* = 7.5 Hz, 2H), 7.37 (d, *J* = 7.0 Hz, 2H), 7.33 – 7.28 (m, 1H), 7.28 – 7.18 (m, 5H), 7.18 – 7.10 (m, 6H), 7.03 (t, *J* = 7.2 Hz, 2H), 6.76 (d, *J* = 1.7 Hz, 1H), 6.67 (t, *J* = 6.7 Hz, 1H). ¹³C NMR (126 MHz, acetone, CS₂) δ 152.9, 150.1, 143.8, 142.5, 142.1, 139.5, 134.0, 132.5, 132.4, 128.6, 128.3, 127.5, 125.8, 124.8, 121.8, 121.3, 120.9, 116.8, 116.6, 115.8, 111.6. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.83. HRMS (ESI) m/z calcd for C₃₅H₂₅BN₃ [M+H]⁺: 498.2136, found 498.2137.




13'H-5l4,8'l4-spiro[dibenzo[b,d]borole-5,7'-pyrido[1',2':1,6][1,5,2]diazaborinino[4,3-f]quinoline], 49.

The general procedure A was followed by using *N*-(pyridin-2-yl)quinolin-5-amine (44 mg, 0.2 mmol, 1 equiv), 2,2'-bis(trifluoro-14-boranyl)-1,1'-biphenyl, dipotassium salt (88 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 57 mg of the product as a white solid (74%). mp >295 °C. ¹H NMR (500 MHz, DMSO) δ 10.41 (s, 1H), 8.96 (d, *J* = 8.6 Hz, 1H), 8.81 (d, *J* = 4.0 Hz, 1H), 7.84 (t, *J* = 7.8 Hz, 1H), 7.73 (d, *J* = 7.8 Hz, 2H), 7.65 (s, 1H), 7.58 (dd, *J* = 8.6, 4.1 Hz, 1H), 7.37 (d, *J* = 8.3 Hz, 1H), 7.24 – 7.13 (m, 5H), 6.98 (t, *J* = 7.2 Hz, 2H), 6.80 – 6.68 (m, 2H). ¹³C NMR (126 MHz, DMSO) δ 160.6, 150.8, 148.9, 147.7, 147.4, 141.1, 140.5, 134.0, 132.5, 130.4, 128.7, 126.8, 126.5, 122.9, 120.2, 119.0, 116.8, 115.6, 114.9. ¹¹B NMR (160 MHz, DMSO) δ -1.82. HRMS (ESI) m/z calcd for C₂₆H₁₉BN₃ [M+H]⁺: 384.1667, found 384.1669.




12H-6l4,7l4-spiro[benzo[4,5]thieno[2,3-c]pyrido[2,1-f][1,5,2]diazaborinine-6,5'-dibenzo[b,d]borole], 50.

The general procedure **A** was followed by using *N*-(benzo[b]thiophen-3-yl)pyridin-2-amine (45 mg, 0.2 mmol, 1 equiv), 2,2'-bis(trifluoro-14-boranyl)-1,1'-biphenyl, dipotassium salt (88 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 55 mg of the product as a yellow solid (71%). mp 159–160 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 10.08 (s, 1H), 7.94 – 7.88 (m, 1H), 7.76–7.72 (m, 1H), 7.72 – 7.65 (m, 3H), 7.38 – 7.31 (m, 2H), 7.26 (d, *J* = 7.0 Hz, 2H), 7.24 – 7.14 (m, 4H), 7.00 (td, *J* = 7.2, 1.0 Hz, 2H), 6.67 (td, *J* = 6.7, 1.2 Hz, 1H). ¹³C NMR (126 MHz, acetone, CS₂) δ 152.4, 149.9, 143.5, 143.3, 141.4, 133.8, 132.6, 130.2, 128.8, 128.3, 125.1, 124.7, 124.3, 120.8, 119.9, 116.5, 116.3. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.43. HRMS (ESI) m/z calcd for C₂₅H₁₈BN₂S [M+H]⁺: 389.1278, found 389.1278.




11-allyl-11H-5l4,6l4-spiro[benzo[c]pyrido[2,1-f][1,5,2]diazaborinine-6,5'-dibenzo[b,d]borole], 51.

The general procedure **A** was followed by using *N*-allyl-*N*-phenylpyridin-2-amine (42 mg, 0.2 mmol, 1 equiv), 2,2'-bis(trifluoro-14-boranyl)-1,1'-biphenyl, dipotassium salt (88 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 µl, 1 equiv), *iPr*₂NEt (0.72 mmol, 119 µl, 3.6 equiv) and toluene (1 mL) to afford 54 mg of the product as a white solid (73%). mp 191–192 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 7.84–7.78 (m, 1H), 7.66 (d, *J* = 7.5 Hz, 2H), 7.63 (dd, *J* = 6.2, 1.7 Hz, 1H), 7.30–7.26 (m, 3H), 7.17 (td, *J* = 7.5, 1.1 Hz, 2H), 7.13–7.06 (m, 2H), 7.03–6.97 (dd, *J* = 10.4, 4.0 Hz, 2H), 6.83 – 6.76 (m, 1H), 6.75 – 6.67 (m, 2H), 6.30 – 6.20 (m, 1H), 5.45 (dd, *J* = 10.7, 0.8 Hz, 1H), 5.33 (dd, *J* = 17.4, 0.8 Hz, 1H), 4.90–4.86 (m, 2H). ¹³C NMR (126 MHz, acetone, CS₂) δ 154.0, 150.4, 143.8, 143.7, 142.7, 133.8, 133.7, 132.4, 128.6, 128.3, 128.0, 125.3, 120.9, 118.6, 117.2, 115.8, 115.4, 53.7. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.88. HRMS (ESI) m/z calcd for C₂₆H₂₂BN₂ [M+H]⁺: 373.1871, found 373.1871.



11-phenyl-11H-5l4,6l4-spiro[benzo[c]pyrido[2,1-f][1,5,2]diazaborinine-6,5'-dibenzo[b,d]borole], 52.



The general procedure A was followed by using *N,N*-diphenylpyridin-2-amine (49 mg, 0.2 mmol, 1 equiv), 2,2'-bis(trifluoro-l4-boranyl)-1,1'-biphenyl, dipotassium salt (88 mg 0.24 mmol, 1.2 equiv), SiCl₄ (0.2 mmol, 24 μl, 1 equiv), *i*Pr₂NEt (0.72 mmol, 119 μl, 3.6 equiv) and toluene (1 mL) to afford 62 mg of the product as a white solid (76%). mp 279-280 °C. ¹H NMR (500 MHz, acetone, CS₂) δ 7.85 (dd, *J* = 10.6, 4.9 Hz, 2H), 7.73 (t, *J* = 7.5 Hz, 1H), 7.69 – 7.59 (m, 5H), 7.50 (dd, *J* = 6.3, 1.5 Hz, 1H), 7.36 (d, *J* = 7.0 Hz, 2H), 7.18 (td, *J* = 7.4, 1.1 Hz, 2H), 7.03 (t, *J* = 7.2 Hz, 2H), 6.88 – 6.81 (m, 1H), 6.75-6.69 (m, 2H), 6.64 (dd, *J* = 7.3, 1.5 Hz, 1H), 6.58 (d, *J* = 9.0 Hz, 1H), 6.23 (d, *J* = 8.3 Hz, 1H). ¹³C NMR (126 MHz, acetone, CS₂) δ 154.1, 150.4, 144.5, 144.4, 142.2, 141.9, 134.5, 133.7, 132.7, 132.4, 131.6, 128.8, 128.6), 127.7, 125.5, 121.1, 117.1, 116.9, 116.1. ¹¹B NMR (160 MHz, acetone, CS₂) δ -1.80. HRMS (ESI) m/z calcd for C₂₉H₂₂BN₂ [M+ H]⁺: 409.1871, found 409.1873.



6-(3,5-bis(trifluoromethyl)phenyl)-6-fluoro-6,11-dihydro-5l4,6l4-benzo[c]pyrido[2,1-f][1,5,2]diazaborinine, 54.

White solid. mp 211-213 °C. ¹H NMR (500 MHz, Acetone) δ 10.18 (s, 1H), 7.98 (d, *J* = 6.4 Hz, 1H), 7.95 – 7.85 (m, 3H), 7.75 (s, 1H), 7.29 (d, *J* = 8.8 Hz, 1H), 7.26 – 7.19 (m, 2H), 7.06 (d, *J* = 7.9 Hz, 1H), 7.02-6.96 (m, 2H). ¹³C NMR (126 MHz, Acetone) δ 150.7, 142.1, 141.7 (d, *J* = 2.2 Hz), 138.6 (d, *J* = 3.4 Hz), 134.0, 132.4, 131.08 (q, *J* = 31.7 Hz), 129.0, 125.5 (q, *J* = 270.3Hz), 124.6, 120.8 (m), 116.0, 115.5, 115.4. ¹⁹F NMR (471 MHz, Acetone) δ -63.1, -169.0. ¹¹B NMR (160 MHz, Acetone) δ 3.51. HRMS (ESI) m/z calcd for C₁₉H₁₂BF₇N₂Na [M+Na⁺]: 435.0874, found 435.0875.

Crystal structure of compound 3



Bond precision: C-C = 0.0047 Å Wavelength=0.71073

Cell: $a=9.5765(11)$ $b=10.1909(12)$ $c=10.8774(16)$

$\alpha=115.915(13)$ $\beta=106.476(11)$ $\gamma=90.377(10)$

Temperature: 294 K

	Calculated	Reported
Volume	905.1(2)	905.1(2)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C23 H19 B N2	C23 H19 B N2
Sum formula	C23 H19 B N2	C23 H19 B N2
Mr	334.21	334.24
Dx,g cm-3	1.226	1.226
Z	2	2
Mu (mm-1)	0.071	0.071
F000	352.0	352.1
F000'	352.12	
h,k,lmax	11,12,12	11,12,12
Nref	3183	3178
Tmin,Tmax		0.630, 1.000

Tmin'

Correction method= # Reported T Limits: Tmin=0.630 Tmax=1.000



AbsCorr = MULTI-SCAN

Data completeness= 0.998 Theta(max)= 25.000

R(reflections)= 0.0612(1860) wR2(reflections)= 0.1903(3178)

S = 1.057 Npar= 234

Crystal structure of compound 4



Bond precision: C-C = 0.0036 Å Wavelength=0.71073

Cell: a=9.1839(14) b=11.2820(14) c=14.148(3)





alpha=90 beta=101.510(17) gamma=90





Temperature: 296 K





	Calculated	Reported
Volume	1436.4(4)	1436.5(4)
Space group	P 21/n	P 1 21/n 1


Hall group	-P 2yn	-P 2yn
Moiety formula	C17 H14 B F N2	C17 H14 B F N2
Sum formula	C17 H14 B F N2	C17 H14 B F N2
Mr	276.11	276.14
Dx,g cm-3	1.277	1.277
Z	4	4
Mu (mm-1)	0.084	0.084
F000	576.0	576.3
F000'	576.24	
h,k,lmax	10,13,16	10,13,16
Nref	2531	2524
Tmin,Tmax		0.585,1.000
Tmin'		
Correction method= # Reported T Limits: Tmin=0.585 Tmax=1.000		
AbsCorr = MULTI-SCAN		
Data completeness= 0.997	Theta(max)= 25.000	
R(reflections)= 0.0502(1605)	wR2(reflections)= 0.1224(2524)	
S = 1.022		Npar= 189

—9.56




















4









6











6









7





















—1.30

























— H2-45
— 144.64
— 141.81
— 138.83
— 137.20
— 135.07
— 129.77
— 128.41
— 126.53






— 1.39

















16




7.93
7.92
7.91
7.91
7.85
7.82
7.67
7.67
7.66
7.64
7.58
7.54
7.53
7.47
7.47
7.43
7.42
7.41
7.33
7.31
7.26
7.25
7.24
7.22
7.21
7.19
7.19
7.18
7.17
7.15
6.83
6.76
6.75
6.74





17



— 150.41
— 143.86
— 139.56
— 134.01
— 132.73
— 132.28
— 130.62
— 129.04
— 127.15
— 125.53
— 125.32
— 124.58
— 123.17
— 120.69
— 117.48
— 114.93
— 113.34




17



17


— 0.74




—9.49

7.85
7.81
7.80
7.78
7.76
7.48
7.46
7.39
7.36
7.33
7.32
7.30
7.17
7.15
7.13
7.11
7.10
7.05
7.04
7.02
6.98
6.88
6.86
6.85

7.34
7.33
7.32
7.24
7.23
7.22



18




1.00

1.17
2.20
1.18
1.26
2.04
1.04
1.00

2.10
2.07


3.5
5.0
4.0
4.5
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0

f1 (ppm)




18

~32.44
~31.55





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0


f1 (ppm)




18









19












-0.06




















22









23



































28





28







8.62
8.60
8.59
8.59
8.14
8.14
7.80
7.46
7.44
7.44
7.43
7.43
7.43
7.43
7.42
7.41
7.41
7.23
7.23
7.22
7.21
7.20
7.11
7.10
7.09
7.08
7.03
7.03
7.02
7.01
7.01
7.00
7.00
6.99
6.81


-2.31
-3.80









2.00
1.00
1.00
2.06
4.94
2.04
0.97


3.03
2.00






















-9.66









— 1.74











—9.65
—7.88
—7.88
—7.87
—7.87
—7.82
—7.82
—7.82
—7.81
—7.81
—7.80
—7.79
—7.79
—7.78
—7.77
—7.77
—7.77
—7.72
—7.70
—7.62
—7.61
—7.60
—7.60
—7.59
—7.59
—7.55
—7.53
—7.50
—7.49
—7.49
—7.37
—7.37
—7.36
—7.36
—7.35
—7.35
—7.34
—7.34
—7.34
—7.33
—7.32
—7.32
—7.23
—7.21
—7.14
—7.14
—7.12
—7.12
—7.10
—7.09
—7.08
—7.07
—7.07
—46.85






— 152.73
— 144.66
— 141.46
— 139.66
— 134.02
— 133.88
— 133.67
— 128.95
— 128.62
— 127.24
— 126.20
— 115.88
— 114.80
— 114.49





— 1.03









—**-9.70**




— 151.75
— 144.24
— 141.57
— 139.67
— 135.37
— 131.70
— 128.10
— 127.72
— 127.66
— 124.35




37





— 4.61





37








38





39





—159.29
—152.56


—144.31
—141.49
—139.48
—136.64
—134.97
—134.85
—127.21
—124.55
—124.52
—124.49
—124.46
—124.44
—124.42
—114.84
—114.47
—114.02




—55.51








—1.53




























-0.89



8.00
7.99
7.92
7.92
7.91
7.91
7.91
7.90
7.89
7.89
7.78
7.77
7.35
7.27
7.25
7.15
7.14
7.13
7.12
7.10
4.99
4.97
4.95
4.94









-9.02

7.93
7.92
7.86
7.85
7.84
7.83
7.83
7.48
7.47
7.46
7.37
7.35
7.26
7.24
7.07
7.04
6.96
6.93
6.86
6.13






—146.47
—141.62
—141.53
—138.95
—137.01
—134.86
—134.68
—129.63
—127.52
—127.28
—127.16
—124.73
—124.52
—114.97
—114.76







¹H 8.74, 8.72, 7.83, 7.81, 7.80, 7.77, 7.75, 7.73, 7.72, 7.67, 7.66, 7.66, 7.26, 7.24, 7.23, 7.17, 7.17, 7.16, 7.14, 7.14, 7.03, 7.03, 7.01, 7.01, 7.00, 7.00, 6.99, 6.99, 6.98, 6.98, 6.97, 6.96, 6.91, 6.89, 6.77, 6.77, 6.76, 6.75, 6.74, 6.74, 6.58, 6.57, 6.56, 6.56









48





—163.94
—150.11
—145.78
—142.54
—142.11
—139.54
—134.95
—132.50
—132.38
—126.62
—127.46
—125.79
—124.79
—121.83
—121.26
—120.86
—116.84
—116.58
—115.83
—111.61

48







48




49




— 160.62
— 150.81
— 148.87
— 147.74
— 147.41
— 141.16
— 140.95
— 134.85
— 132.53
— 130.49
— 128.74
— 126.78
— 126.52
— 122.92
— 120.17
— 119.08
— 116.82
— 115.57
— 114.88




49



— 1.82





49





90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90

f1 (ppm)








50




51







7.86
7.83
7.75
7.73
7.67
7.65
7.63
7.62
7.61
7.51
7.50
7.49
7.37
7.36
7.19
7.19
7.18
7.18




52




—156.12
—156.42
—144.52
—144.37
—141.89
—135.70
—132.70
—132.37
—131.60
—128.85
—128.62
—127.98
—117.15
—116.97
—116.08





52








52




54



— 150.69
— 142.06
— 141.77
— 141.76
— 138.66
— 138.64
— 134.01
— 132.38
— 130.92
— 130.67
— 128.96
— 124.64
— 124.46
— 120.65
— 115.50
— 115.46



— 169.00
— 63.07



-130 -140 -150 -160 -170 -180 -190 -200 -210

f1 (ppm)

20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -220

f1 (ppm)

—3.51

